Anti-TPO Test · Blood

Your thyroid might be under attack right now, and your standard blood work would never show it. Anti-TPO (thyroid peroxidase antibodies) are proteins your immune system produces when it mistakenly targets your own thyroid gland. They can circulate in your blood for years, sometimes a decade or more, before your thyroid hormones actually start to change. By the time TSH climbs on a routine lab panel, the damage is often well underway.

That gap between antibody appearance and hormone disruption is exactly why this test matters for someone focused on prevention. About 11 to 13% of the general population carries these antibodies, and in women over 60, the number rises to roughly 25%. Most of these people have normal thyroid function today. But they carry a measurably higher risk of losing it.

What Thyroid Peroxidase Antibodies Tell You

Thyroid peroxidase is an enzyme your thyroid gland needs to make thyroid hormones. When your immune system produces antibodies against this enzyme, those antibodies can gradually damage thyroid tissue, reducing its ability to produce the hormones that regulate your metabolism, energy, body temperature, and dozens of other functions. This process is the hallmark of Hashimoto's thyroiditis, the most common cause of an underactive thyroid.

The antibodies themselves are found in about 95% of people with Hashimoto's thyroiditis, but only about 60% test positive for a related antibody called thyroglobulin antibody (TgAb). That makes anti-TPO the more sensitive and clinically useful of the two. Anti-TPO is also the only thyroid antibody that has been consistently linked to the risk of progressing from borderline thyroid function to full-blown hypothyroidism in large population studies.

Risk of Progressing to Hypothyroidism

If you already have mildly elevated TSH (a condition called subclinical hypothyroidism, where TSH is high but thyroid hormones are still in range), the presence of anti-TPO antibodies roughly doubles your risk of progressing to overt hypothyroidism. People with positive antibodies progress at about 4.3% per year, compared to 2.6% per year for those without antibodies.

A 13-year community study put numbers to the combined risk. Among women who were antibody-positive, those with TSH between 2.5 and 4.0 mIU/L had a 55.2% chance of developing hypothyroidism over the study period. When TSH was above 4.0 mIU/L, that number climbed to 85.7%. Even with TSH at or below 2.5 mIU/L, 12% still progressed.

What this means for you: if your TSH is "normal" but on the higher end and your anti-TPO is positive, you are not in the clear. You are watching the early phase of a process that has a measurable probability of advancing. Tracking both numbers together gives you far more useful information than either one alone.

Coronary Artery Calcification

One of the more surprising findings in recent research links anti-TPO levels to coronary artery calcium (CAC), a direct measure of plaque buildup in the arteries feeding your heart. In a study of about 3,000 adults followed for five years, people in the highest quarter of anti-TPO levels were roughly 43% more likely to develop new coronary calcium than those in the lowest quarter. Among people with normal thyroid function specifically, the association was even stronger, with about 60% higher incidence of new coronary calcium in the top quarter.

Higher anti-TPO levels were also associated with progression of existing calcium deposits. These associations held even after adjusting for traditional heart disease risk factors and thyroid function, suggesting that the antibodies may mark a type of low-grade immune activation that affects blood vessels independently of thyroid hormone levels.

Mortality Associations

The relationship between anti-TPO and mortality is nuanced and depends on age and sex. The Rotterdam Study, which followed nearly 10,000 adults for a median of 10 years, found that even detectable (not just "positive") anti-TPO levels above 5 kU/L were associated with a 9% increase in overall mortality risk, an 18% increase in cancer-related mortality, and a 21% increase in cardiovascular mortality.

The cardiovascular mortality link was driven almost entirely by men, who showed a 50% higher risk, while women showed essentially no increased cardiovascular mortality risk. This sex difference appeared in multiple studies and remains an active area of investigation.

Interestingly, the picture reverses in the very old. In adults aged 85 and older, elevated anti-TPO was paradoxically associated with a 28% lower mortality risk over five years. This suggests that the immune mechanisms driving these antibodies may play different roles at different stages of life.

The largest analysis to date, pooling over 100,000 adults from 14 cohorts, found no association between anti-TPO positivity and heart attack or stroke after adjusting for age, sex, and TSH. This contrasts with the Rotterdam Study's findings using a lower detection threshold. The discrepancy likely reflects different measurement approaches: standard positivity cutoffs may miss associations that emerge at lower, detectable levels.

Thyroid Cancer

Anti-TPO positivity measured 7 to 10 years before diagnosis was associated with a nearly twofold increase in the risk of papillary thyroid cancer in a nested case-control study of U.S. military personnel. The risk rose with antibody concentration in a dose-dependent pattern: about three times higher risk at levels between 550 and 1,399 IU/mL, and about four times higher at levels above 1,400 IU/mL.

A meta-analysis of over 20,000 subjects confirmed the trend, showing about 57% higher incidence of differentiated thyroid cancer in anti-TPO-positive individuals, along with a higher rate of bilateral tumors. However, in people who do develop papillary thyroid cancer, higher preoperative anti-TPO levels have been associated with a better prognosis and lower recurrence rates, possibly because the underlying immune response also acts against the tumor.

Reference Ranges

Anti-TPO reference ranges vary meaningfully across labs and assay platforms, so always compare your results within the same lab over time. Manufacturer cutoffs for "positive" range from as low as 3.2 IU/mL to as high as 35 IU/mL, and overall variability between methods approaches 50%. The following tiers synthesize the best available population data.

These tiers are drawn from published research including the Tehran Thyroid Study, the Rotterdam Study, and the Busselton Health Survey. Your lab may use different assays and cutpoints. Compare your results within the same lab over time for the most meaningful trend.

Research-derived cutoffs for predicting hypothyroidism are significantly lower than most manufacturer positivity thresholds. One large population study found that 14.77 IU/mL was the optimal cutoff for predicting subclinical hypothyroidism, and 18.38 IU/mL for overt hypothyroidism, well below the 35 to 40 IU/mL threshold most labs use. This means some people with "negative" results on standard lab reports may still carry meaningful risk.

Sex, Age, and Ethnic Differences

Women are two to three times more likely to test positive than men, consistent with the broader pattern of autoimmune disease being more common in women. Prevalence runs about 16 to 18% in women and 8 to 9% in men. Despite this difference in how often the antibodies appear, the reference range thresholds themselves are similar between sexes.

Ethnicity matters as well. In the U.S. NHANES data, anti-TPO positivity was found in about 12.3% of white non-Hispanic adults, compared to 4.5% in Black non-Hispanic adults, with Mexican Americans falling in between. Age shows a complex pattern: the number of new cases is highest in younger adults, but overall prevalence increases with age in cross-sectional snapshots because the antibodies, once present, tend to persist.

Tracking Your Trend

A single anti-TPO result tells you whether your immune system is currently producing antibodies against your thyroid. But the more powerful information comes from watching your trend. Rising titers can signal accelerating autoimmune activity months or years before your thyroid hormones move. Stable or declining titers after a lifestyle or supplement change give you real feedback that something is working.

The biological variation of anti-TPO is about 11.3%, and analytical variation adds another 10.6% on top of that. In practical terms, a change of less than about 30% between two readings at the same lab could be within normal fluctuation. Changes larger than that likely represent a real shift in your immune activity.

If you test positive for the first time, retest in 3 to 6 months at the same lab to confirm the finding and establish your baseline trajectory. If you are making a specific intervention (like selenium supplementation), retest after 3 months to see whether your levels are responding. After that, annual monitoring is a reasonable cadence for most people, with more frequent checks if your TSH is also trending upward.

When Results Can Be Misleading

Anti-TPO antibodies are relatively stable markers, so acute confounders are less of a concern than with many other blood tests. Fasting status and time of day do not appear to affect results meaningfully, and short-term dietary changes or a single workout will not shift your reading. That said, a few factors can distort the picture.

• Smoking: Current smoking is strongly associated with anti-TPO positivity (about three times higher odds), so a positive result in a smoker may partly reflect smoking-driven immune activation rather than isolated thyroid autoimmunity.
• Assay differences: Results from different lab platforms can vary by nearly 50%, which means a "positive" at one lab might read as "negative" at another. Always retest at the same lab when tracking your trend.
• Recovery from severe illness: During and after a serious illness, thyroid function tests can fluctuate (sometimes called sick euthyroid syndrome). While anti-TPO itself is less affected than TSH or free T4, interpreting any thyroid-related marker during or shortly after a hospitalization requires caution.